AC
RCKT icon

Aristides Capital’s Rocket Pharmaceuticals RCKT Stock Holding History

Aristides Capital’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-17,400
Closed -$219K – 317
2024
Q4 		$219K Buy
+17,400
New +$262K 0.04% 217

Other funds holding RCKT

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Aristides Capital's RCKT Position: Q1 2025 in Review

Aristides Capital sold out of Rocket Pharmaceuticals (RCKT) in Q1 2025, closing a stake of 17,400 shares — an estimated $219K sold.

Aristides Capital first reported a position in RCKT in Q4 2024 and held it in 1 quarter. The position peaked at $219K in Q4 2024. 236 funds tracked by Wall St. Rank hold RCKT as of Q1 2025.

  • Aristides Capital reported no remaining Rocket Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Aristides Capital sold 17,400 Rocket Pharmaceuticals shares in Q1 2025, an estimated $219K.
  • Aristides Capital first reported a position in Rocket Pharmaceuticals in Q4 2024 and held it in 1 quarter.
  • Aristides Capital's Rocket Pharmaceuticals position peaked at $219K in Q4 2024.
  • 236 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q1 2025.

Based on Aristides Capital's 13F filing for Q1 2025, filed 14 May 2025.